Related Experiment Video
Updated: Dec 10, 2025
The Tail Suspension Test
Published on: January 28, 2012
Tracking the tail
Alex Friedlaender1, Stephen V Liu2, Alfredo Addeo3
1Oncology, Geneva University Hospitals, Geneva, Switzerland.
Abstract:
Immune-checkpoint inhibitors have deeply changed the therapeutic landscape of advanced non-small cell lung cancer without actionable genomic alterations. Immune-checkpoint inhibitors have become standard front-line therapy, especially among patients with tumours expressing high levels of programmed death ligand-1; yet, many patients do not respond to therapy. This has led to the adoption of front-line combination therapies, administering programmed death-1 inhibitors concomitantly either with other checkpoint inhibitors, chemotherapy or both. Today's approved standard of care includes options with chemoimmunotherapy or dual checkpoint blockade, but each combination has only been compared to chemotherapy alone and no head-to-head trials exist. In cross-trial comparisons, combinations trials appear to show numerically superior responses to single-agent checkpoint inhibitors but the question is whether they ultimately offer a survival advantage. In this manuscript, we summarize and analyse all currently available front-line immune-checkpoint inhibitor trials in non-small cell lung cancer, whether as monotherapy or in combination with chemotherapy, second immunotherapy agents or both. Should standards of care change given the current data? While we ponder this question, we illustrate current data and conclude that the answer lies in tracking the tail of the survival curves.
Insights
Front-line immune-checkpoint inhibitors are standard for advanced non-small cell lung cancer. Combination therapies show promise, but survival advantage requires further analysis of long-term data.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Immune-checkpoint inhibitors (ICIs) revolutionized advanced non-small cell lung cancer (NSCLC) treatment, particularly for PD-L1 positive tumors.
- Despite ICI efficacy, many patients exhibit resistance, prompting the development of front-line combination strategies.
Purpose of the Study:
- To review and analyze all available front-line ICI trials in NSCLC, including monotherapy and combination regimens.
- To evaluate whether current combination therapies offer a survival advantage over single-agent ICI or chemotherapy.
Main Methods:
- Systematic review and cross-trial analysis of published front-line immunotherapy trials in NSCLC.
- Comparison of response rates and survival outcomes across different treatment modalities.
Main Results:
- Front-line combination therapies (chemoimmunotherapy, dual ICI) appear to yield numerically superior response rates compared to single-agent ICIs.
- Head-to-head trial data comparing different combination strategies is lacking.
- The ultimate survival benefit of combination therapies remains under investigation, necessitating long-term survival curve analysis.
Conclusions:
- Current data suggests combination therapies are a viable front-line option for advanced NSCLC, but direct comparative evidence is limited.
- The long-term survival tail of the curves is critical for determining the definitive benefit of these novel combinations.
- Further head-to-head trials are needed to establish optimal front-line treatment standards in NSCLC.
